This new study provides the first real-world safety data for the BBV152 COVID-19 vaccine, recently known as the approved COVAXIN for adolescents.
Since January 2022, potential observational research has been ongoing. 14 days after receipt BBV152 coronavirus vaccineRecruited teenagers and adults were contacted by phone.
Preliminary results were vaccine safety, which was measured by numbers Adverse events after immunization (AEFI) or Vaccine side effects.
The FDA scale was used to grade the severity of side effects after vaccination.
A total of 698 adolescents and 326 adults participated in the study. Side effects were seen in 36.3 percent of adolescents after the first dose and 37.9 percent after the second dose.
What are the side-effects of COVAXIN?
The study found that 15-17 percent were adolescents Systematic involvement. The most common were AEFIs Pain at the injection site And Fever. AEFIs were in the majority Intensity is mild to moderate.
Adolescents with severe and atypical AEFI were diagnosed at 0.9 percent and 0.6 percent, respectively.
Most AEFIs return to normal after 1-2 days. 14 days after the second shot, AEFIs were still present in more than 2 percent of adolescents.
There was no difference in the incidence or pattern of AEFI between adolescents and adults.
Women and those with a history of allergies One has been found 1.5-fold and 3-fold higher risk of side effects In adolescents, according to regression analysis.
During adolescence, COVAXIN has a generally positive short-term safety profile. Adolescent AEFI rates are significantly lower than those reported on mRNA vaccines.
Adolescent women, as well as those with a history of allergies, should be careful.
With some Side effects of COVAXIN Lasting 14 days, a long follow-up is recommended to increase vaccine safety data.
The results of the study were published on the printprint server medrixv.org.
Image Credit: Getty
You were reading: COVAXIN (BBV152) causes fewer side effects in adolescents than mRNA vaccine – study
* Important information: Since medRxiv reveals preliminary scientific research that has not been peer-reviewed, they should not be considered final, should not be used for clinical practice / health-related behaviors, and should not be viewed as established data.